Five years after the World Health Organization declared a global pandemic, there has been progress — and backsliding in the ...

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

The following is a summary of “Transcriptomic insights into early mechanisms underlying post-chikungunya chronic inflammatory ...

Experts at BJMC and SGH are sequencing Chikungunya virus to investigate mutations linked to severe cases and outbreaks in Pune.

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...

Five people have been hospitalized with cardiac and neurological symptoms after getting the chikungunya vaccine.

First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 - ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 - ...

Bavarian Nordic, a Danish biotechnology company specializing in vaccine development, was on 28 February 2025 granted marketing authorization in the EU for their chikungunya vaccine, VIMKUNYA®.

all65 and older, were hospitalized for cardiac or neurologic events following vaccination with IXCHIQ, the only chikungunya vaccine currently licensed in the United States.

Hyderabad: Biological E Limited (BE) announced a partnership with Bavarian Nordic to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income countries (LMIC). BE’s existing ...

Hyderabad-based Biological E Limited (BE) is partnering with Danish firm Bavarian Nordic to manufacture the latter’s Chikungunya vaccine for low and medium income countries (LMIC). The partnership ...